Continuing Pharmacy Education / CE Master List / Addiction Pharmacology and Ibogaine
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Addiction Pharmacology and Ibogaine

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of pharmcogenesy which was a favorite area of Dean Schwarting's.  This presentation discusses Ibogaine and its potential use in addiction treatment.

Learning Objectives

1.    Review the history of iboga, ibogaine, and available forms
2.    Describe pharmacological properties of ibogaine
3.    List contraindicated drugs and conditions with ibogaine
4.     Discuss pharmacologic mechanisms and candidates for ibogaine use

Session Offered

Released:  April 28, 2022
Expires:  April 28, 2025

Course Fee

$15 Pharmacist

ACPE UAN Codes

 0009-0000-22-019-H01-P

Session Code

22SR19-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-22-019-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Benjamin Malcolm, PharmD., MPH
Psychopharmacology Consultant
Spirit Pharmacist LLC
Eugene OR

Faculty Disclosure

Dr. Malcolm has no financial relationships with any ineligible company associated with these presentations.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Download

Post Test Pharmacist

1. Which of the following is TRUE of ibogaine?
A. It was synthesized by researchers in Japan during the early 1900s
B. It is a naturally occurring alkaloid derived from Tabernanthe iboga
C. It is extracted from the iboga root that is native to South America

2. Which of the following is TRUE regarding the pharmacology of ibogaine?
A. It has a long-acting metabolite called noribogaine
B. Its pharmacokinetic profile is remarkably simple
C. It binds exclusively to the opioid receptor

3. In which condition would ibogaine be contraindicated?
A. Allergic rhinitis
B. Pancreatic cancer
C. Prolonged baseline QTc interval

4. Which of the following is a pharmacologic effect of ibogaine supported by observational research?
A. Detoxification of heroin use disorder
B. Detoxification of alcohol use disorder
C. Detoxification of SSRI overdose

5. Which adverse effect has been reported with ibogaine use?
A. Serotonin toxicity
B. Neuroleptic malignant syndrome
C. Ventricular arrythmias